We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Transvaginal Mesh Postmarket Study Shows Continued Risk, FDA Says
Transvaginal Mesh Postmarket Study Shows Continued Risk, FDA Says
The FDA said the benefits of using Coloplast’s Restorelle mesh device for transvaginal repair of pelvic organ prolapse do not outweigh the risks, based on findings from a postmarket surveillance study.